Hexalen

• Antineoplastic Agents
• ATC:L01XX03

• Altretaminum [Inn-Latin]
• HEXAMETHYLMELAMINE
• HMM
• HTM
• HXM
• Hemel
• Hexalen
• Hexastat
• Melamine, Hexamethyl-

• No information avaliable

C₉H₁₈N₆

http://www.rxlist.com/cgi/generic/altretamine.htm

http://www.accessdata.fda.gov/scripts/cder/onctools/summary.cfm?ID=104

No information avaliable

210.28 g/mol

172-174 ^oC

91 mg/L

Solid

1.566

Capsule

For use as a single agent in the palliative treatment of patients with persistent or recurrent ovarian cancer following first-line therapy with a cisplatin and/or alkylating agent-based combination.

Altretamine is a novel antineoplastic agent. The precise mechanism by which altretamine exerts its cytotoxic effect is unknown, although a number of theoretical possibilities have been studied. Structurally, altretamine resembles the alkylating agent triethylenemelamine, yet in vitro tests for alkylating activity of altretamine and its metabolitics have been negative. Altretamine has been demonstrated to be efficacious for certain ovarian tumors resistant to classical alkylating agents. Metabolism of altretamine is a requirement of cytotoxicity. Synthetic monohydroxymethylmelamines, and products of altretamine metabolism, in vitro and in vivo, can form covalent adducts with tissue macromolecules including DNA, but the relevance of these reactions to antitumor activity is unknown.

No information avaliable

No information avaliable

No information avaliable

Humans and other mammals